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Summary: A simultaneous two-site immunoenzymometric assay for creatine kinase MB determination (Hyb-
ritech Tandem-Ε CK-MB) using monoclonal antibodies was evaluated and compared with cellulose acetate
electrophoresis using fluorometric scanning densitometry.
The assay has satisfactory precision (between-day analysis gives a coefficient of Variation between 2.1 and
9.4%) and is not susceptible to interference by concentrations of creatine kinase MM up to 5000 μg/l (3400
U/l) and creatine kinase BB up to 1000 μg/l (1085 U/l). The upper limit of MB isoenzyme concentration in
250 apparently healthy people was 5.5 μg/l. Comparison between the immunoenzymometric assay (y) and
electrophoresis (x) yielded the following linear regression equation: y = 0.37 χ -h 1.9, with a correlation
coefficient of 0.828. The characteristics of the temporal kinetics of MB isoenzyme, calculated by two methods,
in 49 patients with acute myocardial infarction, were nearly identical in terms of the rate of creatine kinase
MB release and the time at which the peak value is obtained, but not in terms of the rate of elimination of
the isoenzyme. The fractional disappearance rate of MB isoenzyme from the circulation was significantly
higher if calculated with Tandem-Ε results rather than with electrophoresis results (—0.035 vs —0.028,
p < 0.001). Whereas in the first day after infarction immunoenzymometric assay and electrophoresis had
the same clinical sensitivity for identifying patients with acute myocardial infarction, in specimens collected
more than 24 hours after the onset of the ehest pain, the clinical sensitivity of the immunoenzymometric
method was lower. Our results show that it is stiU premature to draw definitive clinical conclusions from the
iinmunoassay results.
Evaluierung eines k uflichen immunenzymometrischen Testbestecks zur Bestimmung von Kreatinkinase MB-
Isoenzym mit monoklonalen Antik rpern
Zusammenfassung: Ein gleichzeitig auf zwei Teilkomponenten gerichteter enzymimmunometrischer Assay zur
Bestimmung von Kreatinkinase MB mit monoklonalen Antik rpern (Hybritech Tandem-Ε CK-MB) wurde
ev luiert und mit der CeUuloseacetat-Elektrophorese mit fluorimetrischer Scanning-Densitometrie verglichen.
Die Bestimmung hat eine gen gende Pr zision (VK von Tag zu Tag 2,1 —9,4%) und wird durch Konzentratio-
nen von Kreatinkinase MM bis zu 5000 μ$/1 (3400 U/l) und von Kreatinkinase BB bis zu 1000 μg/l (1085
U/l) nicht gest rt. Die obere Grenze der Konzentration von Kreatinkinase MB bei 250 offenbar Gesunden
war 5,5 μ§/1. Der Vergleich zwischen enzymometrischem Assay (y) und Elektrophorese (x) ergab die folgende
Regressionsgleichung: y == 0,37 x + 1,9 mit einem Korrelationskoeffizienten von 0,828.
Die Characteristika des zeitlichen Verlaufs der Konzentration von Isoenzym MB wurden bei 49 Patienten
mit akutem Herzinfarkt nach zwei Methoden ermittelt. Sie waren bez glich der Freisetzungsrate von
Kreatinkinase MB und der Zeit, zu der der Spitzenwert erhalten wird, nahezu identisch, nicht jedoch bez glich
der Eliminationsrate des Isoenzyms. Die relative Schwundrate des Isoenzyms MB aus dem Kreislauf war bei
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Ermittlung aus den Tandem-E-Ergebnissen signifikant höher als die aus Elektrophoreseergebnissen ermittelte
(-0,035 gegenüber -0,028, p < 0,001). Während enzymimmunometrischer Assay und Elektrophorese am
ersten Tag nach Infarkt die gleiche klinische Empfindlichkeit für die Identifizierung von Patienten mit akutem
Myokardinfarkt aufwiesen, war die klinische Empfindlichkeit der enzymometrischen Methode geringer, wenn
die Probenahme später als 24 Stunden nach Einsetzen des Brustschmerzes erfolgte. Unsere Ergebnisse zeigen,
daß es noch verfrüht ist, endgültige klinische Schlüsse aus den Ergebnissen des Immunoassay zu ziehen.
Introduction
The enzyme creatine kinase (adenosine-5'-triphos-
phate: creatine N-phosphotransferase, EC 2.7.3.2) ca-
talyses the reversible transfer of a phosphate group
from adenosine-5'-triphosphate to creatine. It exists
in the cytoplasm of the cells of human tissues äs a
dimer composed of two subunits, designated M and
B, having a relative molecular mass of 43 000 and
44500, respectively (1). These subunits combine to
produce three dimeric molecular forms designated
creatine kinase MM, MB and BB (2). A fourth isoen-
zyme, isolated from the mitochondria of mammalian
tissues, has been shown to differ from the cytoplasmic
forms in a number of biological and biochemical
criteria (3 — 5). Concentrations (catalytic, mass) of
creatine kinase MB in serum are used to determine
whether cardiac damage has occurred: the low con-
centration of MB in normal serum and in tissues
other than the heart is the basis of its use äs a sensitive
and relative specific indicator in the diagnosis of
acute myocardial infarction (6—11). For these re-
asons, various techniques have been used to isolate
and detect the MB isoenzyme. Three methods are at
present in routine use: electrophoresis on cellulose
acetate or agarose, anion-exchange chromatography
and immunoinhibition, all having different analytical
and clinical advantages and disadvantages (12, 13).
Recently, a promising approach has been the use of
anti-monomer M and anti-monomer B antibodies for
specific detection of creatine kinase MB by "sand-
wich" techniques, with the determination of mass
concentration of the enzyme instead of its catalytic
activity concentration (14-18). The Tandem- cre-
atine kinase MB immunoenzymometric assay (Hybri-
tech Inc., San Diego, CA 92121, USA) uses two
monoclonal antibodies to determine the creatine ki-
nase MB molecule; one monoclonal antibody is di-
rected toward the B subunit and the other toward
the M subunit, producing an assay which is specific
for creatine kinase MB (19).
In this report, we have evaluated the analytical per-
formance of this new commercial kit and compared
results with those obtained with an electrophoretic
technique on acute myocardial infarction patients.
Materials and Methods
Blood samples
Fourty nine patients (43 men and 6 women, with ages ranging
from 44 to 82 years), ädmitted to the Coronary Gare Uüit
of the Civil Hospital of Brescia because of acute myocardial
infarction, were studied. Myocardial necrosis assessment was
based on usual diagnostic criteria (20). Peripheiral venous blood
samples were obtained immediately after admission to the hos-
pital, every 4 hours for the first 24 hours and every 8 hours
for the following 48 hours.
In addition, 250 healthy people (125 women and 125 men,
whose ages ranged from 10 to 70 years), with normal serum
biochemical and haematological tests and without clinical evi-
dence of cardiac and muscle diseases, were studied in of der to
establish the reference level of creatine kinase MB isoenzyme
concentration in serum.
All serum samples were assayed immediately for total creatine
kinase activity; electrophoresis and enzyme immunoassay were
performed within 24 hours after collection with Interim storage
at —20 °C in hennetically sealed plastic Containers.
Assay methods
Measurement of total creatine kinase ;
Total creatine kinase activity was measured with the Standard
method of the Scandinavian Cornmittee on Enzymes (21) with
reagents from Boehringer, Mannheim, FRG, on a Cobas Bio
centrifugal analyzer (F. Hoffmann La Röche and Co., Ltd.,
Basle, Switzerland). Catalytic activity was expressed in terms
of U/l serum (l Unit = l Substrate converted per minute
under optimal conditions) measured at 37 °C; discriminatkm
limits were 160 U/l for women and 190 U/l for inen.
Electrophoresis
We electrophoretically separated creatine kinase isoenzymes on
Titan III cellulose acetate membrane by using the Zip Zone
electrophoresis chamber (Helena Laboratories, Beaumont, TX
77704, USA) and creatine kinase reagents from Böehringer,
Isoenzymes were separated according to the manufacturer's
instruction; after incubation for 25 minutes at 37 °C, the isoeil··
zyme bands were visible by virtue of their fluorescence and
quantitated by fluorometric scanning of the tracings with a
Helena Cliniscan densitometer; the ratio of isoenzymes was
calculated from the integrated area under each *peak and the
enzymic activity of the MB band was calculated from the
product of the total creatine kinase activity and the percentage
of the fluorescence appearing in the MB region. The method
is linear to'500 U/l per band. Samples with values greater than
this should be diluted with saline. Using this method, creatine
kinase MB is undetectable in serum fron» healthy subjects.
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Enzyme immimoassay
The kit assay (product no. R 4993) was performed according
to the manufacturer's direction insert. This assay is a solid
phase two-site immunoenzymometric method. Sample contain-
ing creatine kinase MB is reacted with a plastic bead, which is
coated with a monoclonal antibody directed toward M subunit
of the creatine kinase MB molecule, and with a bovine alkaline
phosphatase-conjugated monoclonal antibody directed against
an antigenic site on the B subunit of the same creatine kinase
MB molecule. Unbound conjugate is removed by washing. A
chromogenic Substrate is added and the amount of its turnover
is determined colorimetrically; the creatine kinase MB concen-
tration present in the sample is directly proportional to the
colour intensity. Results quantified by comparing sample re-
sponse with that of creatine kinase MB calibrator (lyophiiized
human serum containing purified human creatine kinase MB)
of known concentration, are reported in micrograms per litre.
The assay procedure is s follows. Place a single antibody-
coated bead into each 12 χ 75 mm plastic test tube. Add 100
μΐ of antibody conjugate and 100 μΐ of zero diluent (human
serum containing no detectable concentration of creatine kinase
MB) or calibrator or serum sample (in duplicate). Shake the
assay tubes to ensure mixing and incubate the tubes for two
hours on a horizontal rotator set, at room temperature. Add
2 ml of wash solution (composition not available from manu-
facturer) to each tube, aspirate the liquid and repeat this wash
Step twice. Add 200 μΐ of Substrate rcagent 0?-nitrophenyl-
phosphate) to each tube and incubate for 30 minutes at room
temperature. The reaction is stopped with 1.5 ml of quench
reagent, containing ethylenediaminetetraacetic acid, and the
samples are read in a spectrophotometer at 405 nm; in our
laboratory a LKB 7400 calculating absorptiometer (LKB Pro-
duckter AB, Bromma, Sweden) was used which automatically
calculates the net absorbance for the calibrator or specimens
by subtracting the absorbance of zero diluent.
Characterization of human creatine kinase MM and BB isoen-
zymes
The purified MM and BB isoenzymes of creatine kinase, em-
ployed for specificity studies, were obtained from Calbiochem-
Behring Diagnostics, La Jolla, CA 92037, USA. Crealine kinase
MM (product no. 238407) was purified from human skeletal
muscle and creatine kinase BB (product no. 238397) was pur-
ified froin human brain; the purity of each isoenzyme prep-
aration was determined by electrophoresis on polyacrylamide
gel. The specific aetivity of each purified isoenzyme was calcu-
lated from the total creatine kinase aetivity measured at 37 °C
(see above); total protein concentration was measured by the
procedure of Lowry et al. (22). Final preparations of the BB
and MM isoenzymes were electrophoretically hom geneous
and had specific activities of about 1080 U and 685 U/mg
protein, respectively.
Statistical analysis
Calculations of mean, Standard deviation, coefficient of Vari-
ation, correlation coefficient and linear regression anaiysis were
carried out by Standard methods (23). Since values for the
serum enzymes were not normally distributed, the Statistical
analyses were performed with non-parametric Statistical tests,
with use of the Wilcoxon test for paired observations (23). The
clearance rate$ (Kd) for each isoenzyme were calculated from
the declining slppes of the time^activity curves by linear re-
gression analysis, using a logarithmic scale for enzyme activities
(log-scale y-axis) against the time elapsed since the onset (time
zero) of the characteristic pain of myocardial infarct (x-axis)
(24).
Significanee was established at the level of p < 0.05.
Results
Time course of "sandwich" format ion
The effect of varying the duration of the first incu-
bation is illustrated in figure l. Evidently, "sandwich"
formation is complete within the two hours incu-
bation recommended by the supplier.
A possible advantage of the Tandem-Ε type of assay
is that, since antibody conjugate is added in excess,
small pipetting errors in dispensing it may not be
significant. In fact, under experimental conditions,
the assay response is constant for volumes of anti-
body conjugate ranging between 80 and 120 μΐ.
60 90 120
Incubation time [min]
150 180
Fig. 1. Time course of "sandwich" formation with the Tandem-
E assay for creatine kinase MB.
Standards of 15 (o-o) and 80 (Α-Δ) μg/l were
supplied with the kit. Abscissa: duration of incubation
of the antibody-coated bead with serum specimen and
enzyme-conjugated antibody. Ordinate: absorbance
reading after 30 minute incubation with /j-nitrophenyl-
phosphate solution.
Detection limit
We assessed technical sensitivity by 10 replicate mea-
surements of the zero diluent supplied with the kit.
The mean final absorbance was 0.077 A (Standard
deviation, 0.010 A). The calibrator indicated 0.721 A
per 61 μξ/L The minimal detectable concentration of
creatine kinase MB, defined s that amount giving a
signal exceeding the mean zero signal by three Stan-
dard deviations, was 2.5
Linearity and dose/response curve
In the Standard assay procedure, creatine kinase MB
values up to 120 μg/l generate a linear absorbance
signal. A strongly positive creatine kinase MB serum
was serially diluted with zero diluent; for this speci-
men, the results were 120, 100, 50, 25, 12.5, 6.3 and
3.1 μg/l and final absorbance readings were respect-
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ively 1.405, 1.225, 0.565, 0.303, 0.120, 0.061 and
0.021. This response is highly linear (correlation coef-
ficient, 0.9993; Standard error of estimation, 0.024).
Precision
Precision studies are shown in table 1. Within-run
precision was determined by twenty replicate determi-
nations of three different serum samples in one assay;
between-day precision was determined by ten mea-
surements of three different serum samples over a
series of individually calibrated runs. The coefficients
of Variation for intra- and inter-assay precision were
between 1.8 and 9.4%.
Interference studies
Haemoglobin (up to 2.5 g/l), bilirubin (up to 430
μηιοΐ/ΐ), triglycerides (up to 11 mmol/1), albumin (up
to 150 g/l) and adenylate kinase (up to 2.5 g/l) do
not interfere with the evaluated method.
To confirm the MB isoenzyme specificity of the Tan-
dem-E procedure, we tested the effect of purified
human creatine kinase MM and BB on assay. The
results obtained are presented in table 2. Addition of
concentrations of creatine kinase MM lower than
5000 μg/l (3400 U/l) and of creatine kinase BB lower
than 1000 μg/l (1080 U/l) to serum sample containing
a known concentration of MB isoenzyme did not
alter the assayed response of creatine kinase MB from
this serum sample.
Tab. l. Precision of creatine kinase MB isoenzyme determina-
tion by the evaluated method.
Comparison among the methods
The results of the analytical comparison among the
immunoenzymometric assay ^g/l) and electrophor-
esis (U/l) for 120 individual samples submitted at
random to our clinical laboratory from the Depart-
ment of Cardiology of our hospit l' are shown in
figure 2. The data show considerable scatter; in par-
ticular, at low MB values, the ratio electrophoresis/
immunoenzymometric assay is systematically higher.
Within-run (n = 20)
X(ng/i)
5.5
29.8
43.6
SD
(Mg/1)
0.27
0.95
0.79
CV
(%)
4.9
3.2
1.8
Between-day (n =
X
(Mg/1)
6.5
25.1
41.0
SD
(W )
0.61
1.03
0.85
= 10)
CV(%)
9.4
4.1
2.1
All runs performed with a single lot number of reagent kits.
Tab. 2. Influence of creatine kinase MM and BB on the immu-
noenzymometric determination of MB isoenzyme.
MM
Gig/O
10000
0
2500
5000
0
0
MB
G*g/i)
b
0
41.0
41.0
41.0
41.0
BB
(Mg/1)
0
10000
0
0
500
1000
MB
found
(μ§/0
Undetectable
Undetectable
42.2
36.9
40.6
36.5
Percentage
of decrease
in MB
concentration
_
—
—10%
1%
11%
50 100 150 200 250
Creatine kinase MB (electrophoresis) [U/l]
300
Fig. 2. Correlation of results for creatine kinase MB by elec-
trophoresis (x-axis) with those by immunoenzym-
ometric assay (y-axis). Linear regression analysis yields
a regression equation of y = 0.37 χ + 1.9 (solid line)
with a coefficient of correlation of 0.828 and a Standard
error of the estimate of 19.3. Number of patient samples
is 120.
Reference interval
The concentration of MB isoenzyme in sera from
250 apparently healthy subjects was measured by
the immunoenzymometric method and the reference
interval calculated by employing non-parametric de-
termination of percentiles. The· upper limit of refer-
ence values, defined s 95th percentile, was 5.5 μg/l;
this upper limit was the cut-off value used to define
an above-normal concentration of MB isoenzyme in
the analysis of clinical specimens. Again, there was
no sex-related difference.
Comparison studies in patients with acute
myocardial infarction
Table 3 summarizes the data base of clinical cases
and the results of isoenzyme measurements by immu-
noenzymometric assay and electrophoresis on the 49
patients with acute myocardial infarction, The results,
obtained with both analytical methods, were signifi-
cantly correlated but there were discordant results.
At 10 hours after myocardial necrosis, two patients
with detectable MB band at electrophoresis had MB
isoenzyme concentrations of less than 5.5 μ§/1 (2.0
and 3.3 μg/l, respectively). All specimens collected
between 106 and 24 h urs after the onset of the clinical
Symptoms had abnormal isoenzyme, results by both
analytical methods; moreover, the >immunoenzymo-
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Tab. 3. Summary of results of isoenzyme tests (median value
and ränge) in the course of acute myocardial infarction
(49 patients).
Hours
after
onset
of
ehest
pain
4
10
16
24
48
72
Total
creatine
kinase
catalytic
concen-
tration
(U/l)
157
(45-231)
735
(290-2075)
1103
(366-3563)
1264
(214-6360)
717
(110-3865)
244
(50-1493)
MB
isoenzyme
catalytic
concen-
tration
(U/l)
4.5
(0-24)
153,
(27-581)
238
(39-788)
265
(23-1081)
59
(0-396)
8.5
(0-89)
MB
isoenzyme
mass
concen-
tration
(Mg/1)
6.1
(0-25.2)
65.9
(2.0- 236 J))
110.6
(12.5-294.2)
94.0
(5.6-361.2)
14.5
(0-74.3)
2.5
(0-11.6)
Corre-
lation
ofMB
catalytic
and MB
mass
concen-
tration
r = 0.836
p < 0.001
r = 0.749
p < 0.001
r = 0.640
p < 0.001
r = 0.661
p < 0.001
r = 0.684
p < 0.001
r = 0.605
p < 0.001
metric assay did not identify myocardial infarct pati-
ents earlier than electrophoresis (the sensitivity at 4
hours after the onset of ehest pain was the same,
66% of abnormal test results for both methods).
The data for isoenzyme kinetics in acute myocardial
infarction are presented in table 4. Peak times did
not differ significantly according to methodology and
the peak activity value öf MB isoenzyme by elec-
trophoresis correlates significantly with the peak con-
centration of MB äs measured by immunoenzymo-
metric assay. On the contrary, the fractional disap-
pearänce rates of the MB isoenzyme from the circu-
lation were statistically different if calculated with
the results obtained with the two inethodologies em-
ployed. In confirmation of this, abnormal mass con-
centration of MB isoenzyme in speciinens collected
at 72 hours after the onset of ehest pain were observed
only in the 14% of cases of infarction against 57%
of cases with abnormal enzymatic activity.
Discussion
The objective of this study was to determine whether
the Tandem- assay with monoclonal antibodies
could be used to replace the traditional electropho-
retic technique for measuring creatine kinase MB in
the diagnosis of myocardial infarction.
The analytical data demonstrate that the immunoen-
zymometric assay is a reliable method for quantifi-
cation of serum creatine kinase MB. This assay has
satisfactory precision for clinical application and ad-
equate sensitivity for detecting MB levels encountered
in normal sera. Our precision studies indicate that
the method performs much better than indicated by
Shehan & Haythorn (25). On the other hand, in our
initial experience with this kit, we occasionally ob-
tained discrepant duplicate measurements: particular
attention to the washing steps in the procedure, each
with vigorous decanting, has decreased this problem
of spurious high readings, probably due to unbound
phosphatase activity. Analytical specificity is high:
the failure of pathological values of the BB and MM
isoenzymes to react in the assay suggests that no
spurious high levels should be obtained for inter-
ference phenomena. Advantages of this procedure
are that no special equipment is needed other than a
colorimeter and a single point calibration suffices to
obtain a linear calibration curve for quantitation of
results. Monoclonal antibodies provide two required
criteria for linear immunological reaction: homo-
geneous reactivity and excess reagent (26); the third
requirement is the linear production of a measurable
response by the enzyme-label System, which is alka-
line phosphatase. The main disadvantage is that the
immunoenzymometric method is more time-consum-
ing than conventional electrophoresis. We found that
turnaround times for results from the Tandem pro-
cedure were approximately double those for the elec-
trophoresis (about 3 hours for results by the former vs
l .5 hours for the latter). Therefore, even the evaluated
enzyme immunoassay, like other methodologies, can-
not be performed 24 hours a day or during weekends
Tab. 4. Data for isoenzyme kinetics (median value and ränge) in 49 acute myocardial infarction patients.
Peak time (hours)
Peak value
Fractional disappearance rate
per hour
MB
isoenzyme catalytic
concentration
20.5
(9.4/28.0)
320.9 U/l
(39/1097)
-0.028
(-0.011/-0.050)
MB
isoenzyme
mass concentration
19.3
(10.6/28.2)
130.4 g/l
(12.5/353)
-0.035
(-0.010/-0.056)
Significance
of difTerence
NS
p < 0.001
Correlation
r = 0.614
p < 0.001
r = 0.605
p < 0.001
NS, not significant
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and holidays in a stat lab. Moreover, potential draw-
backs are that falsely positive reactions may result
from the presence of heterophilic antibodies in tested
serum (27) and falsely negative results may be seen
in patients with endogenous anti-B autoantibodies
(28).
Our clinical evaluation was planned to emphasize the
agreement and disagreement in results of the two MB
assays (immunoenzymometric and electrophoretic)
rather than their specificity and sensitivity for the
diagnosis of myocardial infarction. The clinical Un-
dings demonstrate that, for most studied patients,
the early temporal sequence of MB isoenzyine after
infarction was the same by both methods. In particu-
lar, we were not able to demonstrate MB in the blood
after myocardial infarction earlier by Tandem- assay
than by electrophoresis. Results were nearly identical
in terms of the rate of creatine kinase MB release
and the time at which the peak value is obtained but
not in terms of the rate of elimination of the isoen-
zyme. The fractioriäl disappearance rate of MB isoen-
zyme from the circulation was signiflcantly higher if
calculated with Tandem- results rather than with
electrophoresis results and, äs a result of this, the
ratio electrophoresis/immunoenzymometric assay
seemed to increase during the post-infarction period.
Therefore, in the first day after infarction, test results
by immunoenzymometric assay and electrophoresis
had the same diagnostic sensitivity for identifying
patients with acute myocardial necrosis, whereas in
specimens collected more than 24 hours after the
onset of ehest pain, abnormal MB isppnzyine results
were detected less frequently by the Tandem- me-
thod rather than by electrophoresis. The reason for
this is not clear; one explanation for these findings is
that the evaluated assay could recognize merely pro-
tein epitopes dissociated untimely from cellülar native
MB molecule in the peripheric circulation. Certainly,
the use of an immunological assay emplöying mono-
clonal antibodies may supply new biochemical and
clinical Information. The monoclonal antibodies, in-
deed, represent a defined homogeneous reagent in
terms of epitopes, affinity and reactivity, which sup^
plies new perspectives for the standardization and for
the application of immunological determinations of
different molecular forms of the enzymes (29). On
the other hand, in partial contrast with other reports
(30, 31), our results show that it is dangerous to draw
definitive conclusions from the immunoassay results,
äs an exact comparison between enzyme activity and
mass concentration measurements appears not to be
possible.
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